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Abstract 
 
Introduction 
PrEP is defined as daily medicine taken by at-risk individuals to prevent HIV. Although an 
increasing number of individuals are using PrEP, more studies are needed to accurately assess the 
distribution of PrEP use in different populations.  
Existing data suggests that PrEP usage remains low in communities that need it the most. 
Black and Hispanic MSM are significantly less likely to use PrEP compared to White MSM. 
Objectives 
This study hypothesizes that: 
i) African-Americans have lower odds of reporting past/present PrEP use compared 
to white individuals. 
ii) Latino/Hispanic individuals have lower odds of reporting past/present PrEP use 
compared to white individuals. 
iii) Individuals in the 26-35-year age-group have higher odds of reporting past/present 
PrEP use compared to individuals in the 18-25-year age-group. 
iv) MSM individuals have higher odds of reporting past/present PrEP use than non-
MSM individuals.  
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Methods 
Anonymous, multiple-choice questionnaires were administered at the Allies for 
Health+Wellbeing Booth during both events. A total of 267 individuals were surveyed. 
IRB approval was not obtained prior to data collection but post hoc IRB permission to 
publish the data was obtained.  
Results 
Out of the 263 individuals included in the study,  34(12.9%) individuals were past/present 
PrEP users. Individuals in the 26-35-year age-group were significantly more likely to report 
past/present PrEP use compared to 18-25-year-olds. African-Americans were significantly more 
likely to report past/present PrEP use compared to White individuals. Native-Americans were 
significantly more likely to report past/present PrEP use compared to White individuals. Being an 
MSM was significantly associated with past/present PrEP usage (compared to non-MSM).  
Conclusion 
The public health significance of this study is that it provides a snapshot of past/present 
PrEP usage in the surveyed population. A PrEP to Need ratio (PnR) can be calculated with the 
help of this data and can be used to assess PrEP usage over time. This data can then be used as a 
basis to carry out more research to develop interventions to increase PrEP use in populations who 
are at a high risk of HIV acquisition with low rates of PrEP use. More demographic data is needed 
from future studies to accurately assess PrEP use. 
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1.0  HIV in the United States 
Awareness about HIV/AIDS started to spread in the USA after reports of multiple cases of 
Kaposi’s sarcoma and Pneumocystis Carinii Pneumonia in the early 1980s. By 1984, the viral 
origin of HIV had been established. Similar cases were also increasingly documented in other parts 
of the world 1. At the end of 1990, the United States had between 628,000 to 988,000 PLWH 2. 
Today, around 1.1 million PLWH are in the Unites States3.  The number of new HIV cases 
diagnosed in the United States in 2017 was 38,739 4. Although the number of new cases per year 
has remained relatively constant since 2012 4, new HIV diagnoses affect various subpopulations 
at different rates. The highest number of new HIV cases are seen in Black, male to male sexual 
contact cases. The lowest number of new HIV cases in 2017 was seen in White heterosexual 
women(see Figure 1 below) 4.  When looking at HIV incidence data by age group, the 25-29-year 
age group had the highest incidence of HIV followed by the 20-24, 30-34, 35-39, 40-44, 45-49, 
50-54, 55-59, 15-19, 60-64 and ≥ 65-year groups in decreasing magnitudes respectively 5. While 
examining HIV incidence by gender the incidence in males is 4 times higher than in females5. The 
distribution of HIV incidence by race shows us that African Americans have the highest incidence 
of HIV followed by Hispanic/Latino, mixed races, Native Hawaiian/Pacific Islander, Native 
American/Alaska Native, White and Asian in decreasing order respectively 5 (Table 1 highlights 
this data in more detail).  
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Figure 1 New HIV diagnoses in different subpopulations 2017 
This figure shows the incidence of HIV in different subpopulations. The Black MSM subpopulation had the highest 
number of new HIV diagnoses followed by the Hispanic/Latino MSM subpopulation.4 
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Table 1 Incidence of HIV by age and race 
 
Diagnoses of HIV infection by year of diagnosis and selected characteristics, 2012-2017 – United States. 5 
1.1.1 The HIV landscape of Allegheny County and Pennsylvania 
There were 36,086 individuals living with HIV (PLWH) in Pennsylvania at the end of 
201822. As of December 2018, there were 26,188 male and 9,898 female PLWH in the state22. 
An estimated 17,723 African American, 11,049 White, 5,632 Hispanic, 1,296 multiracial, 337 
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Asian/Pacific and 49 Native American PLWH were present in Pennsylvania at the end of 2018 
22. While splitting the data by age group, Pennsylvania had 549, 1,672, 10,582, 11,558, 7,853, 
and 3,872 PLWH in the age groups of <13, 13-19, 20-29, 30-39, 40-49 and over 49 respectively, 
at the end of 201822. There were 14,112 PLWH who self-identified as Men who have sex with 
men  in Pennsylvania at the end of 201822.  
The rate of new HIV diagnosis in Pennsylvania in 2017 was 8.4 per 100,000 population22. 
The highest rate by county was 31.2 per 100,000 population (Philadelphia County)22. Most of the 
individuals diagnosed with HIV in 2017 were from Philadelphia and Allegheny Counties22.  
There were an estimated 2,965 PLWH at the end of 2018 in Allegheny County22. The rate of new 
HIV infections for 2018 in Allegheny County is 7.4 per 100,000 population22 , which is below 
the state average of 8.4 (the rate has decreased compared to 2016, where the rate was 10.8 per 
100,000 population)22. There were 85 new HIV cases and 28 new AIDS cases in Allegheny 
County in 201823.  
Between 2009 and 2017, the annual number of reported new HIV infections in Allegheny 
County were between 100 and 142 24. In 2017, the majority (around 80%) of new HIV infections 
occurred in males, and the most common age group affected was 20-29 years 24. African American 
males had a higher incidence rate (44.4 per 100,000 population) of HIV infection as compared to 
white males (8 per 100,000 population) 24. In women, 70% of new HIV infections were in African 
American women (14 out of 20 new infections in 2017) 24. In 2017, around 61% of new HIV 
infections occurred in men who have sex with men 24.  
There were 26 newly diagnosed AIDS cases in Allegheny County in 2017 24. Eighty one 
percent (21 out of 26) of the newly diagnosed individuals were male, half (13 out of 26) of the new 
AIDS cases were in whites and 42% (11 out of 26) were in African Americans 24. 
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1.2 PrEP 
Pre-Exposure Prophylaxis (PrEP) for HIV is medication intended to be taken by HIV 
negative individuals to prevent the acquisition of HIV 6. PrEP use has been predicted to reduce the 
sexual transmission of HIV by 99% when used daily 6. When taken consistently, PrEP has also 
been shown to reduce the risk of HIV transmission by 74% in individuals who inject drugs 6. On 
July 12th, 2012 the Food and Drug Administration (FDA) approved Truvada as pre-exposure 
prophylaxis for HIV 7.  As of now, Truvada and Descovy (approved in October 2019) are the only 
FDA approved drugs for PrEP. According to the CDC, PrEP is recommended for: 
i) Serodiscordant couples6 
ii) Individuals not in mutually monogamous relationships with someone who recently 
tested negative for HIV 6. 
iii) Gay/bisexual men who have had condomless anal sex in the past 6 months 6. 
iv) Gay/bisexual men who have been diagnosed with a sexually transmitted infection in 
the past 6 months 6. 
v) Heterosexual males who report inconsistent condom use with partners of unknown HIV 
status 6.. 
vi) Individuals at a substantial risk of HIV infection ( individuals who inject drugs or 
women with bisexual male partners)6. 
vii)  . PrEP is also recommended for people who have injected drugs in the past 6 months 
and have shared needles or have been in drug treatment in the past 6 months 6 .  
 
Since it has been proven to be extremely effective when taken daily, it is  important to 
make PrEP and other HIV prevention modalities easily accessible to populations at the highest risk 
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of HIV acquisition (Black MSM, MSM). PrEP should always be used with a condom as it does 
not offer any protection against other sexually transmitted infections such as chlamydia and 
gonorrhea 6.  
1.2.1 Barriers and Facilitators of PrEP 
Barriers 
PrEP has an effectiveness of 99% when taken daily 6. This makes it an indispensable tool 
in preventing HIV. The  uptake, adherence and use of PrEP unfortunately, is rife with barriers.  
Barriers of PrEP uptake and use can be subdivided into two types, structural barriers and individual 
barriers 8. 
Some of the structural barriers to PrEP uptake include lack of access to PrEP, stigma 
surrounding PrEP, the cost of PrEP and lack of provider knowledge or prescribing providers. PrEP 
is only available by prescription; only certified clinicians can prescribe PrEP. Even after PrEP use 
has been initiated, regular clinician access is required for periodic blood testing (HIV testing and 
kidney function test) and follow up. Therefore, lack of access to a provider can impede PrEP use. 
Telemedicine can overcome these barriers by bringing PrEP to the people. The availability of 
online PrEP (NuRX, Plushcare) and TelePrEP has the potential to improve PrEP uptake using 
telemedicine, thus putting more people in touch with PrEP providers.  
Stigma is another important barrier to consider. Often, PrEP users experience stigma from 
members of the society and even some healthcare providers. Stigma is usually experienced from 
healthcare providers and members of the society8. According to a study done by Jaiswal et al, 
stigma experienced from healthcare providers pertained mainly to concerns about talking to a 
doctor about their sex life. Stigma experienced from members of the society came from concerns 
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of being perceived as HIV positive by others and having to explain their use of PrEP to others 
(family, romantic and sexual partners, and religious communities).Stigma is divided into 
experienced and anticipated stigma 8. Anticipated stigma from family, romantic and sexual 
partners, and religious communities negatively affects PrEP uptake and use8. Stigma of associating 
PrEP with HIV and having multiple sexual partners also played a role in negatively affecting PrEP 
use. 
The cost of PrEP is another barrier to consider. For the uninsured, PrEP  costs 1844.75 
dollars for a 30-day supply10,26 (for both Truvada and Descovy). This puts it out for reach for many 
subpopulations, particularly those that are at high risk for HIV acquisition10. Medication assistance 
programs can be used by uninsured individuals who lack prescription drug coverage to get PrEP 
for free 48.Although PrEP is covered by most insurance plans and state-funded Medicaid schemes, 
the cost follow up bloodwork is not. Paying for follow up tests poses yet another barrier to 
continued PrEP use49. 
The dearth of prescribing providers has led to a barrier to PrEP prescriptions. A lack of 
clear guidelines on who should prescribe PrEP has also led to confusion between primary care 
providers and HIV specialists, thus leading to more barriers to PrEP uptake 8. 
Some individual barriers to PrEP use are side effects of the drug, lack of PrEP awareness, 
lack of one’s risk perception and concerns about events/situations that might occur while taking 
PrEP 8,11. 
The adverse effects encountered while taking PrEP deter some from taking or sticking to  
PrEP8. According to a study done by Holloway et al. that used an online survey to gather data on 
PrEP uptake, adherence and discontinuation among 761 young MSM in California form July 2015 
to August 2015, 21 individuals discontinued PrEP. The top reasons for PrEP discontinuation 
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included being concerned about long term consequences of PrEP use (33.3%), being unable to 
afford a prescription for PrEP (28.6%), using other strategies to reduce HIV risk (23.8%), 
forgetting to take PrEP everyday (23.8%) and being unable to afford the required medical visits 
for PrEP (19%)39. The top reason that deterred individuals from using PrEP was concern about 
side effects. 
Glidden et al studied the symptoms, side effects and adherence in PrEP users during the 
first 3 months of the iPrEX Open label extension (OLE) study (an 18-month open label, multi-site 
PrEP cohort taking daily PrEP). Out of 1092 participants that were studied for side effects of PrEP, 
there were 56 (5%) interruptions in PrEP dispensations. PrEP discontinuation was temporary in 22 
participants and permanent in 34. The most common adverse effects reported to cause 
discontinuation of PrEP were nausea/abdominal pain, diarrhea, skin problems/itching, headache 
and flatulence 45.  
Golub et al. studied the effect of barriers and facilitators of PrEP acceptability and PrEP 
adherence motivation. The study was carried out among MSM and transgender women divided 
into 2 groups- those willing and those unwilling to take PrEP. The participants were then  given a 
list of PrEP use barriers to rate according to importance. The study stated that concerns about the 
long-term effects of PrEP on health and concerns about side effects were rated as most important 
by both groups11. A greater percentage of those who were unwilling to take PrEP deemed the 
barriers as important11. Expectations to indulge in anal sex, HIV medications not working if one 
becomes HIV positive and having to explain their PrEP use to others were also some other barriers 
that were important (a greater percentage of those who were unwilling to take PrEP deemed these 
barriers as important)11.  
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There are also some logistical barriers to PrEP use. Regularly seeing a provider and getting 
a blood test (HIV testing and Kidney Function test) every 3 months, makes PrEP unappealing to 
some. 
Taking a pill every day is also cumbersome enough for some individuals to not consider PrEP to 
prevent HIV.  
Facilitators 
There are few factors that enhance overall PrEP usage especially among sexual minority 
men (gay, bisexual men and other MSM) and transgender women8,11. Sexual health counseling, 
high risk perception, increased pleasure associated with condomless sex, not having to pay for 
PrEP and access to free sexual health care/monitoring while on PrEP are some of the facilitators 
to PrEP use8,11.  
When part of support for the use of PrEP, counseling about sexual health was found to promote 
PrEP use. It has been noted that men who have sex with men are more willing to use PrEP when 
offered in conjunction with one on one counselling8.Viewing oneself as an individual with a high 
risk of HIV acquisition increases the odds of using PrEP11. The desire to engage in condomless 
sex makes individuals seek out alternate HIV prevention modalities like PrEP or PEP, which 
increases an individual’s willingness to use PrEP11. Being part of an insurance plan that provides 
PrEP for free is a huge incentive for high risk individuals to use PrEP. Additional care provided, 
such as treatment for STIs like gonorrhea and chlamydia, testing for STIs and sexual counseling 
while obtaining PrEP can be an appealing reason to initiate and continue PrEP use8,11. 
  10 
1.3 PrEP Awareness 
When individuals are unaware of PrEP, they cannot make the informed decision of using 
PrEP. Being unaware of the existence of an HIV prevention modality puts many subpopulations 
at a higher risk of HIV acquisition, especially when PrEP has proven to be extremely effective. 
Awareness of PrEP has remained low despite being available commercially since 2012. 
Although PrEP awareness has increased since it was available (especially among MSM)19, levels 
of awareness are still low in individuals of color (compared to white individuals), individuals over 
the age of 40 (compared to those below the age of 40)32,33,34.  Unfortunately, awareness is the 
lowest in Black MSM and transgender women33,34.  
Figure 2 13 shows the levels of PrEP awareness, discussion with healthcare providers, and 
usage among White, Hispanic and African American MSM in 23 urban areas in the year of 2017. 
 
Figure 2 PrEP awareness, discussion and use in White, Latino and African American MSM 
Figure 2 shows the levels of PrEP awareness, discussion and usage among White, Hispanic and African American 
MSM in 23 urban areas.13 
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1.4 PrEP Use in the United States 
PrEP was marketed to the US market as a once-a day pill taken to prevent HIV. Truvada 
(approved for PrEP in 2012) and Descovy (approved for PrEP in 2019), both made by Gilead 
Sciences are the only medications available for preexposure prophylaxis against HIV.  
PrEP must be prescribed by a clinician after an appointment where the individual receiving 
PrEP will be provided guidance on how to use PrEP. Counseling on safe sex practices is also 
provided. The individual must then take PrEP daily and return for blood testing –(HIV testing and 
Kidney function test) every three months. Online PrEP options, with online clinician appointments 
and at-home blood tests (NuRx, Plushcare,  etc.) can also be used when convenient 43,44. 
According to the CDC, around 1.1 million individuals can potentially benefit from HIV 
prevention strategies like PrEP 17, but in 2017, only 118,249 individuals used PrEP27 (Figure 3 
shows the number of individuals who can benefit from PrEP, broken down by race 17).  
PrEP use is slowly starting to increase in the United States42. One cross-sectional study of 
population level data, using data from a national health data company estimated that the number 
of PrEP users had increased from 765 users in 2012 to 118,249 in 2017 27. According to a study 
done by the CDC in 2017, 35% of gay and bisexual men at risk for HIV were using PrEP 42. The 
distribution of PrEP use, however, is not uniform across different states and subpopulations.  
PrEP to Need ratio (PnR) is defined as the number of PrEP users divided by the number of 
new HIV diagnoses. A lower PnR indicates an unmet PrEP need. In examining differences in PnR, 
across country, southern states have lower PnR compared to the rest of the US 27.  
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Figure 3 Number of adults who could potentially benefit from PrEP 
Estimated number of adults who could potentially benefit from PrEP, United States, 2015.17 
 
One study that used the National Prescription database to quantify PrEP use among MSM 
in urban areas showed an  increase in PrEP use from 6% to 36% between 2012 and 2016 14. Another 
study that looked at PrEP use in African American MSM between the years of 2014 and 2017 
using serial cross sectional survey assessments at Black Gay Pride events in 6 cities reported that 
PrEP use among African American MSM increased from 4.5% (in 2014) to 15.5% (in 2017)19. 
Despite these increases, PrEP use remains low among gay and bisexual men of color42.   
According to the CDC, prevalence of HIV in communities is an important factor that can 
influence the likelihood of developing an HIV infection15, which is why  increasing the use of 
PrEP in high risk subpopulations and communities (populations mentioned in Figure 3) is crucial 
to prevent new HIV infections.  
Although the South accounts for more than half of the new HIV diagnoses, only 30% of 
all PrEP users are from the South 16. New York, Washington D.C,  Massachusetts, Rhode Island 
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and Washington had the highest number of PrEP users in 2017 16. The rate of PrEP use in the 
Northeast was double that of the other regions (West, South and Midwest) 16.  
The number of male PrEP users outnumber female PrEP users by a factor of 16. Males 
account for around 94% of total PrEP users 16. Figure 4 shows the distribution of PrEP use between 
males and females 18. 
 
 
Figure 4 Number of male and female PrEP users 
This figure shows the number of male and female PrEP users18 
 
Individuals in the age group of 25-34 had the greatest number of PrEP users followed by 
the 35-44,45-54, 18-24, 55-64 and ≥65 age groups respectively 18. This pattern mimics the HIV 
incidences in these groups 5. Table 2 describes the distribution of PrEP use among the genders 
and different age groups 18.  
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Table 2 PrEP use by gender and age group between 2014-2016 
 
Annual number of persons aged ≥ 16 years prescribed HIV preexposure prophylasix, by selected 
characteristics – IQVIA* longitudinal prescription database, United States, 2014-2016.18 
 
1.5 Correlates of PrEP Use 
There are multiple factors indirectly associated with the usage of PrEP  (factors that don’t 
directly affect the access and use of PrEP but those that can help predict PrEP use). Some of 
these are residential instability in the recent past (negatively associated with PrEP usage), current 
health coverage, got tested for HIV in the past 6 months, having a higher income, higher 
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education levels (college degree and up)19,20,21.  The number of male sexual partners an 
individual has, has also been shown to significantly predict PrEP use (higher number of male 
sexual partners increased the likelihood of PrEP use)19,21. Studying the correlates of PrEP use can 
shed some light on some of the disparities that exist with PrEP usage. Using this knowledge, 
interventions can be developed to improve PrEP uptake in subpopulations with low PrEP usage. 
Optimizing the way PrEP is promoted, to target groups with low PrEP usage (but high HIV risk) 
is one such intervention. 
According to Mayer, et al. (2016),  prior use of post exposure prophylaxis, or PEP 
(medications used to prevent HIV acquisition, taken after potential exposure, usually for 28 
days) was  shown to significantly predict  PrEP use21. The use of PEP in the past also meant that 
these individuals were more likely to be aware of PrEP through clinician counseling (provided 
during their visit to acquire PEP)21. Prior PEP users were also seen as an important 
subpopulation for targeted PrEP use promotions21.  A history of sexually transmitted infections 
(STIs) was also associated with increased PrEP use21 (STI counseling by healthcare providers 
could be contributing factor to PrEP knowledge and use at the time of STI diagnosis).  
Okafor, et al. (2017), who conducted a study to assess correlates of PrEP use among 
MSM in Los Angeles between February 2015 and January 2017, noted that having sex with an 
HIV positive partner was shown to significantly predict  recent PrEP use20. The use of poppers 
(alkyl nitrate-based substances ingested through inhalational route for recreational purposes) was 
also shown to significantly predict  PrEP use20. Popper use was also associated with other 
activities that put individuals at a high risk of HIV acquisition, like condomless anal sex20. 
Being ‘out’ to one’s doctor and colleagues was also shown to be associated with higher 
rates of PrEP usage20. However, the study used participants with prior involvement in studies 
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related to PrEP use facilitation which the authors claim could have inflated the rate of PrEP use 
in the study population.20.  
According to Eaton, et al. (2018), drug use in the recent past was more likely to be 
reported by PrEP users (compared to non-PrEP users)19. Eaton et al found that the use of 
stimulants (cocaine, methamphetamines and ecstasy) was shown to significantly predict  PrEP 
use; this finding  was rather worrisome, as these substances may have a negative impact on 
medication adherence19 .  
1.6 PrEP Adherence 
One study that used semi-structured interviews involving MSM to determine factors 
affecting adherence noted that disruptions in daily routine and use of alcohol and 
methamphetamines was associated with low PrEP adherence rates36.  This study also stated that 
long-acting PrEP agents can improve adherence rates in the future36.   Another study ( a systematic 
review) noted that social factors such as stigma, low risk perception, low decision-making power, 
an unacceptable dosing regimen, side effects and the logistics of daily life were all factors that 
hampered PrEP adherence37. 
One demonstration project and safety study reported that the most common reason for 
missing pills were participants ‘forgetting to take the pill’, ‘being away from home’ and ‘being 
busy with other things’ 38.  
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1.7 Public Health Significance 
There is a dearth of studies describing the demographics of PrEP usage in Pittsburgh and 
Allegheny County. City- and County- level data can help streamline efforts to optimize PrEP usage 
by pointing out populations with high HIV risk and low PrEP uptake. PrEP use data demonstrating 
the differences in PrEP use among different subpopulations exclusively in Pittsburgh are scarce. 
This study aims to provide  some information on PrEP usage in different demographic 
subpopulations in Pittsburgh and fill in that gap. The data from this study can then be used in 
projects targeting increased PrEP use in these subpopulations. 
Roth et.al used data from a local organization in Pittsburgh (AIDS Free Pittsburgh/AFP) 
to conduct a serial   cross-sectional analysis of  PrEP awareness in Allegheny county 41 . The 
survey, conducted by AFP, was made available to several organizations to distribute among their 
client and patient bases. Out a total of N=2036 surveys that were collected, 191 were analyzed 
(incomplete/incorrect responses, individuals who were categorized as females, those who 
identified as straight cisgender males and those who self-identified as HIV positive were 
excluded).   The study found gender and sexual orientation to be significant predictors of PrEP 
awareness. Individuals above the age of 55 were significantly less likely to be aware of PrEP 
compared to 18-24-year-old individuals, gender non-conforming individuals were found to be less 
aware of PrEP compared to males (bivariate analysis only). Multiracial individuals were more 
aware of PrEP compared to White individuals (bivariate analysis only). Being African 
American/Asian was not significantly associated with PrEP awareness compared to Whites.  
Studies like this can help us identify populations with low PrEP use and thus develop 
strategies to combat it. Demographic data on PrEP use is constantly needed to assess the 
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penetration of PrEP as a preventive modality. Low rates of PrEP use uncovered from data 
collection can then be addressed by interventions that increase PrEP awareness and use.  
Close monitoring of PrEP users can help unearth new problems that occur with PrEP usage 
and distribution. New side effects of the drug, problems with PrEP access, problems with insurance 
policies, problems with adherence and many other barriers can be assessed with data collected at 
the city and county level. This data can then be used by the Allegheny County Health Department 
to resolve these issues by developing appropriate policies and interventions, aimed at future PrEP 
users. 
The aim of this study is to analyze whether significant differences exist in the levels of past 
or present PrEP use among different demographics like age, race, gender in the study population 
(individuals at the Pittsburgh Pride 2019 and Too Hot for July 2019 who took the survey)  and 
within the MSM subpopulation and compare this to national statistics.  This study hypothesizes 
that : 
i) Individuals that identify as African American have lower odds of reporting past or
present PrEP use when compared to white individuals.
ii) Individuals that identify as Latino/Hispanic have lower odds of reporting past or
present PrEP use when compared to white individuals.
iii) Individuals in the 26-35-yearage group have higher odds of reporting past or
present PrEP use when compared to individuals in the 18-25-year age group.
iv) Individuals who identify as MSM have higher odds of reporting past or present
PrEP use than those who do not identify as MSM.
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Updated PrEP use data is needed to assess parameters such as PrEP to Need ratios 
in different populations.  The findings of this study can be used as a guide for future 
research on PrEP use statistics(like calculating the PrEP to Need ratios in different 
populations) in Pittsburgh and Allegheny County. PrEP use data can then be used to 
develop targeted strategies and interventions to increase PrEP awareness and use in 
sociodemographic groups with low reported PrEP use and high HIV risk, and address PrEP 
use differences. 
1.8 Public Health Implications 
i) Training of healthcare professionals:
a) Pinto et al mentions the purview paradox, which was found to be a major barrier
to PrEP uptake51. According to the paradox, HIV specialists do not see HIV
negative patients often, whereas PCPs, who often see high-risk HIV negative
patients are not trained in providing PrEP51. Training PCPs to correctly
prescribe PrEP can dramatically improve uptake.
b) Increasing awareness and positive PrEP attitudes among non-prescribing
providers (staff at HIV test sites and AIDS service organizations) can help
educate and link clients to locations offering PrEP51.
ii) Funding for Services:
a) Advocating for expansion of health insurance that covers PrEP50
b) Increasing funding to medication assistance programs50
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c) Funding medication costs, adherence and counseling/monitoring services (like
Telemedcine/telePrEP)50
iii) Structural changes to increase access:
a) Stigma experienced from some healthcare providers is a barrier to PrEP use8.
Cultural competency training to address bias against PrEP users should be
integrated into existing competency training regimens. Maloney et al conducted
online focus groups to assess stigma in healthcare that prevent MSM from
seeking PrEP information and prescriptions from their PCPs50. A common
theme among most participants was the need for a non-judgmental relationship
with the PCP before disclosure of one’s sexual orientation and sexual health
discussions including HIV prevention and PrEP50. This highlights the need to
address stigma to facilitate sexual discussions with their patients.
b) Increasing the number of PrEP providing facilities in locations with low PrEP
uptake can improve PrEP uptake.
c) Paying  for PrEP was found to be a major barrier to many MSM according to
Jaiswal et al8. Reducing the cost of PrEP and introduction of generic options for
PrEP can help alleviate these barriers.
iv) Policy changes:
a) Medication policies put in place by private insurance companies exacerbate
barriers to PrEP implementation51. Policies that require prior authorization
paperwork and strict requirements regarding completion of tests prior to
authorization and prescription renewal impede PrEP implementation and use51.
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A change to such policies to ones that provide easy PrEP access is essential in 
improving PrEP implementation and use. 
b) Putting  policies in place to combat the purview paradox to improve PrEP
uptake51. Policies that mandate PCPs to prescribe PrEP can positively impact
PrEP implementation.
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2.0 Methods 
The study, a non-randomized questionnaire-based survey that utilized convenience 
sampling at two LGBTQ focused events, viz the Pittsburgh Pride 2019 and Too Hot for July 
2019 was conducted to describe the demographic distribution of past or present PrEP usage of 
those individuals who visited the Allies for Health + Wellbeing booth at these events. The paper 
surveys were completely anonymous and were completed at the booth by the individual using a 
clipboard.. IRB approval was not sought before conducting the survey and gathering the data but 
post hoc approval to use the data from the IRB was obtained (no IRB numbers are provided for 
post hoc approvals). The letter of approval from the IRB can be found in the appendix. 
The survey was administered by two volunteers stationed at the Allies for Health + 
Wellbeing booth at both events. Volunteers at the stall were pointing visitors to complete the 
survey after their visit. The Too Hot for July event took place on the 6th of June 2019 at the Ace 
Hotel and the Pittsburgh Pride took place on the 8th and 9th of June 2019 at Ft. Duquesne Blvd, 
Pittsburgh, PA.  
2.1.1 Demographic Measures 
The focus of this study was to describe the demographic distribution of past or present 
PrEP usage in the individuals surveyed. Table 3 shown below shows the questions asked in the 
survey. The survey asked questions about the participants’ age, sex at birth, gender identity, sexual 
preference, sexual orientation, past or present PrEP use discontinuation status and race. 
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2.1.2 Outcome Measure 
Past or present PrEP use was assessed using one question with four options (only one 
response allowed). The question “Have you ever used PrEP (Pre-Exposure Prophylaxis)/ 
Truvada? Had the following four options: “Yes (more than 6 months ago)”, “Yes (in the past 6 
months)”, “Yes (I am currently on PrEP)” and “No”. Individuals selecting the following options 
– Yes (more than 6 months ago), Yes (in the past 6 months) and Yes ( I am currently on PrEP)
was put into the past/present PrEP use category.    Anyone selecting ‘No’ was put into the No 
past/present PrEP use category. 
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Figure 5 Questions from the survey 
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2.2 Analytic Sample 
The study included individuals who visited the Allies for Health + Wellbeing both at the 
2 events and agreed to take the survey. A total of 267 individuals took the survey. Four 
completed questionnaires were excluded for selecting 2 genders in the gender identity question. 
Out of 263 surveys, 34 reported current or past PrEP use (229 individuals had never used PrEP). 
Responses by transgender individuals were determined by assessing the option choices in the sex 
assigned at birth and gender identity questions. Responses by men who have sex with men  were 
determined by assessing the option choices in the sex assigned at birth and sexual preference 
questions ( any individual who selected their sex at birth as male and had male as one of the 
options in the sexual preference question, regardless of other choices was considered as MSM). 
2.3 Data Analysis 
The purpose of this study was to analyze differences in past or present PrEP use within age 
groups, race, gender, and HIV transmission groups; and to conduct within-group analyses of past 
or present PrEP use differences by race/ethnicity among MSM. This study hypothesizes that : 
i) Individuals that identify as African American have lower odds of reporting 
past or present PrEP use when compared to white individuals. 
ii) Individuals that identify as Latino/Hispanic have lower odds of reporting 
past or present PrEP use when compared to white individuals. 
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iii) Individuals in the 26-35-yearage group have higher odds of reporting past 
or present PrEP use when compared to individuals in the 18-25-year age 
group. 
iv) Individuals who identify as MSM have higher odds of reporting past or 
present PrEP use than those who do not identify as MSM. 
The different demographics included were age, race, gender and MSM status. . A total of 
263 surveys were analyzed. Predictor variables for the outcomes were age, race, gender, and MSM 
status. The use of PrEP was the outcome variable. Independent demographic factors that were 
significantly associated with past or present PrEP use were determined by performing Chi-Square 
and Fisher’s Exact tests (used with nominal variables with a small sample size with an expected 
value of < 5). Odds ratios with one predictor and one outcome were determined by using bivariate 
logistic regression. Past or present PrEP use rates were then compared by every demographic factor 
(one by one), controlling for all other factors. This was conducted using multivariable logistic 
regression which then produced adjusted odds ratios (aOR), which were then used to determine 
the association of different demographic covariates with past or present PrEP use. The purpose of 
these tests was to determine possible demographic associations of past or present PrEP use within 
the sampled population and the MSM subpopulation. 
The results obtained from chi square tests and logistic regression analyses were used to 
determine associations of PrEP use within the study population and the study MSM population. 
Then, comparisons will be drawn between the results of the study and National PrEP use statistics.  
Stata SE 15.0 (StataCorp LP, College Station, TX) was used to perform all statistical 
analyses. 
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Replies to the “Have you ever stopped using PrEP? If so, why?” question were grouped 
together by common themes. Three broad themes emerged among the replies, viz. ‘side effects’, 
‘being in a past or  relationship’ and ‘other’. Any reply that mentioned a side effect as the reason 
for past or present PrEP discontinuation was categorized as ‘Side effects’. Replies that mentioned 
being in a relationship (either currently or in the past) as the reason for past or present PrEP 
discontinuation were categorized as ‘being in a past or present relationship’. All other replies were 
categorized as ‘other’.   
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3.0 Results 
Population characteristics of the individuals included in the study are described in the 
tables below (Table 3 and Table 4). Out of the total 267 individuals who took the survey, only 34 
(12.7%) had reported past or present PrEP use. The tables below (Tables 3 and 4) divides the 
entire study population and the MSM subpopulation based on past or present PrEP use and 
demographic characteristics. Chi square and/or Fisher’s exact test values corresponding to the 
effect of sociodemographic variable categories on past/present PrEP use are also given.  
Gender, race and MSM vs non-MSM categories were found to be significantly associated 
with past or present PrEP use. While looking at gender distribution of the population, 46.7% 
(n=123) were categorized as cisfemales (individuals who were assigned as female at birth and 
currently identify themselves as female), 39.5% (n=104) were categorized as cismales (indi- 
viduals who were assigned as male at birth and currently identify themselves as male), 5.7% 
(n=15) identified themselves as non-binary on the survey, 2.6% (n=7) identified themselves as 
non-conforming, 1.9% (n=5) were categorized as transgender female (individuals who were 
assigned as male at birth and currently identify themselves as female) and 3.4% (n=9) were 
categorized as transgender male (individuals who were assigned as female at birth and currently 
identify themselves as male). The survey population distribution by race was as follows : 18.6% 
(n=49) identified as African American, 1.5% (n=4) identified themselves as Native American, 
2.6% (n=7) self-identified as Asian, 2.2% (n=6) self-identified as Latino/Hispanic, 6.8% (n=18) 
selected the Mixed Race option for the race question, 1.9% (n=5) selected the ‘Other’ race 
category and 66.1% (n=174) identified themselves as White. There were 82 (31.17%) individuals 
categorized as men who have sex with men (individuals who were assigned as male at birth, 
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selected male in the sexual preference question regardless of other replies and identified 
themselves male, non-conforming or non-binary were considered as MSM for this study). 
Age group was not found to be significantly associated with past or present PrEP use. 
The age distribution of the surveyed population was as follows : 44.8% (n=118) of the 
individuals surveyed were in the 18-25 year age group, 30% (n=79) were in the 26-35 year age 
group, 16.3% (n=43) were in the 36-45 year age group, 4.1% (n=11) were in the 46-55 year age 
group and 4.5%  (n=12) were in the 55+  age group.  
Age was not found to be a significant predictor of past or present PrEP use ( χ2 = 6.44, 
Fisher’s exact p value = 0.117). PrEP use proportions for the different age groups were - No PrEP 
use: 109 (92.37%) | PrEP use: 9 (7.62%) |Total: 118 for the 18-25 year age group; No PrEP use: 
64 (81.01%) | PrEP use: 15 (18.98%) |Total: 79 for the 26-35 year age group; No PrEP use: 36 
(83.72%) | PrEP use: 7 (16.27%) |Total: 43 for the 36-45 year age group; No PrEP use: 9 (81.81%) 
| PrEP use: 2 (18.18%) |Total: 11 for the 46-55 year age group and No PrEP use: 11 (91.66%) | 
PrEP use: 1 (8.33%) |Total: 12 for the 55+ year age group. 
Gender was found to be a significant predictor of past or present PrEP use (χ2 = 45.02, 
Fisher’s exact p value = 0.000). PrEP use proportions for the different gender categories were - 
No PrEP use: 123 (100%) | PrEP use: 0 (0%) |Total: 123 for the cisfemale category; No PrEP 
use: 77 (74.03%) | PrEP use: 27 (25.96%) |Total: 104 for the cismale category; No PrEP use: 14 
(93.33%) | PrEP use: 1 (6.66%) |Total: 15 for the non-binary category; No PrEP use: 6 (85.71%) 
| PrEP use: 1 (14.28%) |Total: 7 for the non-conforming category; No PrEP use: 3 (60%) | PrEP 
use: 2 (40%) |Total: 5 for the transgender female category and No PrEP use: 7 (77.77%) | PrEP 
use: 2 (22.22%) |Total: 9 for the transgender male category. 
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Race, was also found to be a significant predictor of past or present PrEP use (χ2 = 23.25,   
Fisher’s exact p value = 0.000). PrEP use proportions for the different race categories were - No 
PrEP use: 36 (73.46%) | PrEP use: 13 (26.53%) |Total: 49 for the African-American category; 
No PrEP use: 2 (50%) | PrEP use: 2 (50%) |Total: 4 for the Native-American category; No PrEP 
use: 5 (71.42%) | PrEP use: 2 (28.57%) |Total: 7 for the Asian category; No PrEP use: 4 
(66.66%) | PrEP use: 2 (33.33%) |Total: 6 for the Latino/Hispanic category; No PrEP use: 18 
(100%) | PrEP use: 0 (0%) |Total: 18 for the mixed category; No PrEP use: 4 (80%) | PrEP use: 1 
(20%) |Total: 5 for the other category and No PrEP use: 160 (91.95%) | PrEP use: 14 (8.04%) 
|Total: 174 for the white category. 
Being part of the MSM population was found to be a significant predictor of past or 
present PrEP use (χ2 = 53.29, p = 0.000). PrEP use proportions were No PrEP use: 53 (64.63%) | 
PrEP use: 29 (35.36%) |Total: 82 for the MSM category; No PrEP use: 176 (97.23%) | PrEP use: 
5 (2.76%) |Total: 181 for the non-MSM category. 
Within the MSM subpopulation, no demographic variable (age, gender or race) was 
found to significantly predict past or present PrEP use (χ2 = 4.04, p = 0.400 for age group; χ2 = 
0.376, p = 0.829 for gender and χ2 = 11.47, p = 0.075 for race) . PrEP use proportions for the 
different age categories within the MSM population were - No PrEP use: 16 (66.66%) | PrEP 
use: 8 (33.33%) |Total: 24 for the 18-25-year category; No PrEP use: 16 (59.25%) | PrEP use: 11 
(40.74%) |Total: 27 for the 26-35-year category; No PrEP use: 8 (53.33%) | PrEP use: 7 
(46.66%) |Total: 15 for the 36-45-year category; No PrEP use: 4 (66.66%) | PrEP use: 2 
(33.33%) |Total: 6 for the 46-55-year category and No PrEP use: 9 (90%) | PrEP use: 1 (10%) 
|Total: 10 for the 55+ category. 
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PrEP use proportions for the different gender categories within the MSM population were 
No PrEP use: 49 (64.47%) | PrEP use: 27 (35.52%) |Total: 76 for the cismale category; No PrEP 
use: 3 (75%) | PrEP use: 1 (25%) |Total: 4 for the non-binary category and No PrEP use: 1 (50%) 
| PrEP use: 1 (50%) |Total: 2 for the non-conforming category. 
 PrEP use proportions for the different race categories within the MSM population were - 
No PrEP use: 12 (42.85%) | PrEP use: 9 (57.14%) |Total: 21 for the African-American category; 
No PrEP use: 1 (33.33%) | PrEP use: 2 (66.66%) |Total: 3 for the Native-American category; No 
PrEP use: 1 (33.33%) | PrEP use: 2 (66.66%) |Total: 3 for the Asian category; No PrEP use: 0 
(0%) | PrEP use: 2 (100%) |Total: 2 for the Latino/Hispanic category; No PrEP use: 4 (100%) | 
PrEP use: 0 (0%) |Total: 4 for the mixed category; No PrEP use: 4 (100%) | PrEP use: 0 (0%) 
|Total: 4 for the other category and No PrEP use: 31 (68.88%) | PrEP use: 14 (31.11%) |Total: 45 
for the white category. 
Out of the 34 past or present PrEP users, 15 (44.1% of PrEP users) answered the question 
‘Did you  ever stop using PrEP? If so, Why?’ as ‘Yes’. Out of the 15 responses, 14 (41.1% of 
PrEP users) individuals filled out the blank space stating their reason for stopping PrEP. One 
individual who answered ‘Yes’, left the blank empty and one individual left an obscure response 
– ‘CWOC’. The 14 responses were as follows: ‘stomach problems’; ‘the dreams’; ‘ I have no sex
life!’; ‘scary’; ‘have a partner’; ‘GI side effect’; ‘irritation’; ‘prostate cancer’; ‘depression; not 
having sex’; ‘side effects/adjusting’; ‘relationship’; ‘in a long term relationship’; ‘ Dr. would not 
renew, all tests were good, now have a PCP that prescribes PrEP’ and ‘CWOC’. Being in a 
relationship and side effects were the most common reasons for stopping PrEP. The responses 
were divided into 3 main categories: “side effects”, “being in a past or present relationship” and 
“other”. 
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Table 3 Characteristics of the individuals who took the survey, divided by past or present PrEP use. N=263 
Demographic Variable PrEP Use(%) No PrEP Use(%) Total  p and χ2-values 
AGE 
p = 0.117 (FE) 
χ2 Value : 6.44 
18-25 9 (7.62%) 109 (92.37%) 118 
26-35 15 (18.98) 64 (81.01%) 79 
36-45 7 (13.95%) 36 (86.04%) 43 
46-55 2(18.18%) 9 (81.81%) 11 
55+ 1 (8.33%) 11 (91.66%) 12 
GENDER 
p = 0.000 (FE) 
χ2 Value : 45.02 
Cis-Female 0 (0%) 123 (100%) 123 
Cis-Male 27 (25.96%) 77 (74.03%) 104 
Non-Binary 1 (6.66%) 14 (93.33%) 15 
Non-Conforming 1 (14.28%) 6 (85.71%) 7 
Transgender Female 3 (60%) 2 (40%) 5 
Transgender Male 2 (22.22%) 7 (77.77%) 9 
RACE 
p = 0.000 (FE) 
χ2 Value : 23.25 
African American 13 (26.53%) 36 (73.46%) 49 
Native American 2 (50%) 2 (50%) 4 
Asian 2 (28.57%) 5 (71.42%) 7 
Latino/Hispanic 2 (33.33%) 4 (66.66%) 6 
Mixed 0 (0%) 18 (100%) 18 
Other 1 (20%) 4 (80%) 5 
White 14 (8.04%) 160 (91.95%) 174 
MSM vs Non-MSM 
p =  0.000 (χ2) 
χ2 Value : 23.25 
MSM 29 (35.36%) 53 (64.63%) 82 
Non- MSM 5 (2.76%) 173 (97.23%) 181 
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Table 4 Characteristics of the MSM population who took the he survey, divided by past or present PrEP use. 
N=82 
Demographic Variable PrEP Use(%) No PrEP Use(%) Total  p and χ2-values 
AGE 
p = 0.40 (χ2) 
χ2 Value : 4.04 
18-25 8 (32%) 16 (68%) 24 
26-35 11 (46.66%) 16 (59.25%) 27 
36-45 7 (46.66%) 8 (53.33%) 15 
46-55 2(33.33%) 4 (66.66%) 6 
55+ 1 (10%) 9 (90%) 10 
GENDER 
p= 0.829 (χ2) 
χ2 Value : 0.376 
Cis-Male 27 (34.17%) 49 (64.47%) 76 
Non-Binary 1 (25%) 3 (75%) 4 
Non-Conforming 1 (50%) 1 (50%) 2 
RACE 
p = 0.075 (χ2) 
χ2 Value : 11.47 
African American 9 (42.8%) 12 (57.14%) 21 
Native American 2 (66.66%) 1 (33.33%) 3 
Asian 2 (66.66%) 1 (33.33%) 3 
Latino/Hispanic 2 (100%) 0 (0%) 2 
Mixed 0 (0%) 4 (100%) 4 
Other 0 (0%) 4 (100%) 4 
White 14 (30.43%) 31 (69.56%) 45 
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3.1 Regression Analysis 
Full sample bivariate regression analyses 
The relationship between age, gender, race, MSM status , within MSM demographics 
(age, gender and race) and past or present PrEP use was analyzed using bivariate and 
multivariable logistic regression. Odds ratios (OR) and adjusted odds ratios (aOR) with 
corresponding 95% confidence intervals of the analyses  for the entire study population (N=263) 
are shown in Table 5 and ORs and those for analyses within the MSM population are shown in 
Table 6. Since there were no past or present PrEP users in the cis gendered female and mixed-
race categories, the outputs for their respective ORs and aORs were empty.   
Using the 18-25-year age group as the age reference category, the 26-35 year age group 
had significantly higher odds of reporting past or present PrEP use than the 18-25-year age group 
in the bivariate regression analysis (OR = 2.83; 95% CI: 1.17, 6.85). The 36-45, 46-55 and 55+ 
age groups were not significantly more likely to report past or present PrEP use than individuals 
in the 18-25-year age group (OR = 2.35 ; 95% CI: 0.81, 6.77; OR = 2.69; 95% CI: 0.50,   14.38; 
OR = 1.10; 95% CI: 0.12, 9.51 respectively). 
Using cis gendered males as the gender reference category, the non-binary, non-
conforming and transgender female categories were not significantly more likely to use PrEP (in 
the past or the present) than cis gendered males  (OR = 0.20 ; 95% CI: 0.025, 1.62; OR = 0.47; 
95% CI: 0.05, 4.12; OR = 4.27; 95% CI: 0.67, 26.99 respectively). Individuals in the transgender 
male category were not significantly more likely to report past or present PrEP use than cis 
gendered males in the bivariate regression analysis ( OR= 0.81; 95% CI: 0.15, 4.16). 
The White race category was used as the reference group that other races were compared 
with. The African American and Native American race categories had significantly higher odds 
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of reporting past or present PrEP use than the White race category in the bivariate regression 
analysis ( OR = 4.12, 95% CI: 1.78, 9.53; OR = 11.42, 95% CI: 1.49, 87.42 respectively). 
Latino/Hispanic individuals had marginally significant higher odds of using PrEP (in the past or 
present) when compared to White individuals in the bivariate analysis (OR = 5.71, 95% CI: 
0.965,33.99). According to the bivariate analysis, individuals in the Asian and Other race 
categories were not significantly more likely to use PrEP (in the past or present) than individuals 
in the White race category (OR = 4.57, 95% CI: 0.81, 25.74; OR = 2.85, 95% CI: 0.29, 27.33 
respectively). Since there were no past or present PrEP users in the Mixed-Race category, the 
output for OR was empty.  
The individuals who were categorized as MSM had significantly higher odds of reporting 
past or present PrEP use compared to those individuals not in the MSM category in the bivariate 
analysis. (OR = 19.26, 95% CI: 7.10, 52.22).  
 
Within-MSM bivariate regression analyses 
The within MSM bivariate analyses were carried out using the same reference categories 
for age, gender and race as previously mentioned (The 18-25-year age group for age, the cis male 
category for gender and the white race category for race). The 26-35, 36-45, 46-55 and 55+ year 
old age groups were not significantly more likely to report past or present PrEP use than 
individuals in the 18-25 year age category (OR =1.37, 95% CI: 0.43, 4.31; OR = 1.75, 95% CI: 
0.46, 6.56; OR = 1.00, 95% CI: 0.14, 6.67; OR = 0.22, 95% CI: 0.02, 2.07 respectively). 
Individuals in the non-binary and non-conforming gender categories were also not 
significantly more likely to use PrEP (in the past or present) than individuals in the cis male 
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category in the within MSM analysis (OR = 0.60 ; 95% CI: 0.059, 6.10 and OR = 1.81; 95% CI: 
0.10, 30.18 respectively). 
Since there were no past or present PrEP users in the cis-female and transgender male 
categories, the output for OR was empty. 
African-American, Native American and Asian individuals were also not significantly 
more likely to report past or present PrEP use than White individuals in the within MSM analysis 
(OR = 1.66 ; 95% CI: 0.56, 4.84; OR = 4.42; 95% CI: 0.37, 52.99; OR = 4.42; 95% CI: 0.37, 
52.99 respectively). 
 
Full sample multivariable regression analyses 
The same reference groups were used in the multivariable analysis of the entire study 
population and the within MSM population ( 18-25 year for age, cis gender males for gender, 
White for race, non-MSM individuals for the MSM vs non-MSM category) . 
In the multivariable analysis, none of the age groups were significantly more likely to use 
PrEP ( in the past or present) compared to the reference group i.e the 18-26 year age group (aOR 
= 2.05; 95% CI: 0.68, 6.11, aOR = 2.34 ; 95% CI: 0.61, 9.03; aOR = 2.09; 95% CI: 0.30, 14.36; 
aOR = 0.27; 95% CI: 0.02, 2.91 for the 26-35, 36-45, 46-55 and 55+ age groups respectively). 
Multivariable analysis of the gender category revealed that individuals in the non-binary and 
non-conforming categories were not significantly more likely to report past or present PrEP use 
than the reference group i.e cis-males (aOR = 0.70 ; 95% CI: 0.06, 7.59 and aOR = 1.79; 95% 
CI: 0.10, 32.33 respectively). Since there were no past or present PrEP users in the cis gendered 
female category, the output for aOR was empty. The aOR outputs for the transgender female and 
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transgender male categories were non-estimable due to small sample sizes in their respective 
categories. 
African American individuals were  significantly more likely to report past or present 
PrEP use compared to white individuals (aOR= 3.25; 95% CI: 1.21, 8.72). Past or present PrEP 
use in Latino/Hispanic individuals was marginally more significant when compared to white 
individuals (aOR= 17.87; 95% CI: 0.94, 336.70). Individuals in the Native American race 
category were not significantly more likely to use PrEP (in the past or present) in the 
multivariable analysis than the reference group i.e White individuals (aOR = 6.35, 95% CI: 0.53, 
74.98). Multivariable analysis for individuals in the Asian and Other race categories were not 
significantly more likely to report past or present PrEP use than individuals who were White 
(aOR = 3.61, 95% CI: 0.27, 47.51 and aOR = 0.78, 95% CI: 0.07, 8.19 respectively). Since there 
were no past or present PrEP users in the Mixed-Race category, the output for aOR was empty. 
Individuals who were categorized as MSM had significantly higher odds of reporting past or 
present PrEP use compared to those individuals not in the MSM category in the multivariable 
analysis. (aOR = 54.35, 95% CI: 8.78, 336.28).  
 
 Within-MSM multivariable regression analyses 
In the within MSM multivariable analyses none of the age groups (26-35, 36-45, 46-55 
and 55+) were significantly more likely to report past or present PrEP use compared to the 
reference group i.e the 18-26 year age group (aOR = 1.24; 95% CI: 0.38, 4.00, aOR = 1.80 ; 95% 
CI: 0.47, 6.91; aOR = 1.25; 95% CI: 0.18, 8.71; aOR = 0.23; 95% CI: 0.02, 2.22 for the 26-35, 
36-45, 46-55 and 55+ age groups respectively). 
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Multivariable analysis of the gender category in the MSM population revealed that 
individuals in the non-binary and non-conforming categories were not significantly more likely 
to report past or present PrEP use than cis males  (aOR = 0.71 ; 95% CI: 0.06, 7.46 and aOR = 
1.66; 95% CI: 0.09, 29.21 respectively). 
Multivariable analysis of the race category in the MSM population revealed that 
individuals in the African American, Native American and Asian categories were not 
significantly more likely to report past or present PrEP use than white individuals ( aOR = 1.63, 
95% CI: 0.55, 4.80; aOR = 4.31, 95% CI: 0.35, 52.15; aOR = 4.73, 95% CI: 0.33, 66.07 
respectively). 
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Table 5 Odds ratios (OR) and adjusted Odds ratios (aOR) from bivariate and multivariable logistic 
regression models assessing associations between age, gender, race, MSM status (predictors) and PrEP Use 
(outcome) among individuals who answered surveys at 2 LGBTQ focused events in Pittsburgh, 2019 (n=263) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There were a total of 263 survey responses analyzed (n=263). The Odds Ratio values (OR) were derived 
using bivariate logistic regression, while the adjusted Odds Ratio values (aOR) were derived using 
Multivariable logistic regression (all other demographic factors were controlled for).Base variables labeled 
REF were used as a reference that other variables were compared to. # :denotes marginal significance. 
Values in bold are significant. Non- estimable results were due to very few individuals in that category and 
empty results were due to that category having no (zero) past or present PrEP users 
Demographic Variable 
 
PrEP Use OR (95% CI) PrEP Use aOR (95% CI) 
 
AGE   
   
18-25 REF REF 
26-35 2.83     (1.17, 6.85) 1.60     (0.52, 4.94) 
36-45 2.35     (0.81, 6.77) 2.10     (0.55, 8.00) 
46-55 2.69     (0.50, 14.38) 1.73     (0.25, 11.92) 
55+ 1.10     (0.12, 9.51) 0.26     (0.02, 2.63) 
   
GENDER   
   
Cis-Male REF REF 
Cis-Female Empty (No PrEP Use) Empty (No PrEP Use) 
Non-Binary 0.20     (0.025, 1.62) 0.70     (0.06, 7.54) 
Non-Conforming 0.47     (0.05, 4.12) 1.76     (0.09, 31.58) 
Transgender Female 4.27     (0.67, 26.99) 3.66     (0.33, 39.66) 
Transgender Male 0.81     (0.15, 4.16) Non- estimable 
   
RACE   
   
White REF REF 
African American 4.12     (1.78, 9.53) 2.43     (0.87, 6.78) 
Native American 11.42   (1.49, 87.42) 5.78     (0.48, 68.4) 
Asian 4.57    (0.81, 25.74) 3.56     (0.28, 44.8) 
Latino/Hispanic 5.71#     (0.96, 33.99)# 19.07 (0.852, 426.567) 
Mixed Empty (No PrEP Use)                     Empty (No PrEP Use) 
Other 2.85     (0.29, 27.33)                      0.94     (0.08, 10.27) 
   
MSM vs Non-MSM   
   
Non-MSM REF REF 
MSM 51.85    (12.03, 223.44)               75.75     (11.29, 507.92) 
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Table 6 Odds ratios (OR) and adjusted Odds ratios(aOR) from bivariate and multivariable logistic regression 
models assessing associations between age, gender, race (predictors) and PrEP Use (outcome) among MSM 
who  answered surveys at 2 LGBTQ focused events in Pittsburgh, 2019 (n=82) 
 
 
Demographic Variable 
 
PrEP Use OR (95% CI) PrEP Use aOR (95% CI) 
 
AGE   
   
18-25 REF REF 
26-35 1.85     (0.61, 5.61)                           1.50     (0.47, 4.77) 
36-45 1.85     (0.49, 6.94)                           2.01     (0.52, 7.75) 
46-55 1.06     (0.15, 7.06)                           1.49     (0.21, 10.42) 
55+ 0.23     (0.02, 2.19)                            0.25    (0.02, 2.46) 
   
GENDER   
   
Cis-Male REF REF 
Cis-Female Empty (No PrEP Use) Empty (No PrEP Use) 
Non-Binary 0.60     (0.059, 6.10)                        0.71     (0.06, 7.52) 
Non-Conforming 1.81     (0.10, 30.18)                        1.72     (0.09, 30.65) 
Transgender Female 5.44     (0.539, 54.92) 3.71     (0.34, 39.80) 
Transgender Male Empty (No PrEP Use)                      Empty (No PrEP Use) 
 
   
RACE   
   
White REF REF 
African American 2.28     (0.82, 6.32)                          2.13     (0.75, 6.00) 
 
Native American 4.57     (0.38, 54.65)                        4.87     (0.40, 58.86) 
Asian 4.57     (0.38, 54.65)                        3.96     (0.31, 49.73) 
Latino/Hispanic Empty (No MSM Users)             Empty (No MSM Users)             
Mixed Empty (No MSM Users)             Empty (No MSM Users)             
Other Empty (No MSM Users)             Empty (No MSM Users)             
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4.0 Discussion 
PrEP use is still low among subpopulations that need it the most in the United States12,13.  
This study aimed to shed light on the demographic distribution of past or present PrEP use in the 
surveyed sample and draw comparisons to national PrEP use statistics. Further studies on 
distribution and long-term trends of PrEP use are required to deploy appropriate interventions to 
increase uptake. The results show that at the two events in Pittsburgh,  African American 
individuals, Native Americans, and men who have sex with men were more likely to have used 
PrEP in the past or currently use PrEP when compared to their corresponding reference groups 
(although the limited sample size and the method of sampling used, viz. convenience sampling, 
mean that these results cannot be generalized).  
Individuals in the 26-35 age group were significantly more likely to have used PrEP in the 
past or currently be on PrEP compared to their counterparts in the 18-25-year age group according 
to the results from the bivariate regression analysis (OR = 2.83, 95% CI:  1.17, 6.85) [although the 
limited sample size and the method of sampling used, viz. convenience sampling, mean that these 
results cannot be generalized]. In comparison, the CDC states that, PrEP usage has been higher in 
the 25-34-year age category when compared to the 18-24-year age group18, which is similar to the 
results in my study. One study, done by Holloway et al, showed similar findings where individuals 
in the age group of 25-29 had significantly more PrEP users than individuals in the 18-24-year-old 
age group.39 
According to this study ,men who have sex with men were significantly more likely to 
report past or present PrEP use as compared to those who were not in the MSM category, this 
represents one of the most important populations that PrEP is geared towards, according to the 
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CDC6 (although the limited sample size and the method of sampling used, viz. convenience 
sampling, mean that these results cannot be generalized). 
Within the MSM population, 21 individuals were African American, out of which 9 
individuals (42.85%) were past or present PrEP users. 45 individuals were White, 14 (31.11%) of 
these individuals were past or present PrEP users. Out of the 2 Latino/Hispanic MSM, 2 (100%) 
were PrEP users (although the limited sample size and the method of sampling used, viz. 
convenience sampling, mean that these results cannot be generalized).  
Kuhns et al conducted a longitudinal study of HIV risk in young MSM (N=394). The 
study (conducted between December 2014 and January 2016) showed that only 4.7% of Black 
young MSM had ever used PrEP. Past or present PrEP use in White, Hispanic and Other races 
were 29.5%, 11.7% and 6.9% respectively. Past or present PrEP use was the lowest among Black 
young MSM  46.  
The rates of past or present PrEP usage in White MSM (in Kuhn’s study) are similar to 
this study, but the rates in African American and Latino individuals are different. Past or present 
PrEP use was higher in African American and Latino/Hispanic MSM when compared to White 
MSM in this study. The above-mentioned study looked at PrEP usage rates in the cities of 
Houston and Chicago, which may differ from rates of PrEP usage in Pittsburgh. 
According to a study by Finlayson et al which looked at PrEP use among MSM in  20 
urban areas between 2014 and 2017 prevalence of  PrEP use in MSM is  35% in 201714.  This is 
similar to the prevalence of MSM PrEP use in the population used in this study (39.5%). 
More studies need to be conducted to assess the distribution and impact of PrEP usage in 
different subpopulations. The data from these studies can then help identify subpopulations in 
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need of increased PrEP and guide interventions that can increase PrEP usage effectively in these 
subpopulations.   
In the study there were no cis-gendered female past or present PrEP users,which is 
consistent with CDC data stating that PrEP awareness and PrEP use is very low among females 
when being compared to data for males13,18. Since PrEP is also meant to be used by heterosexual 
women who have condomless sex with partners of unknown HIV status6, concentrating efforts to 
promote PrEP use among women can be a possible step to prevent new HIV cases in the future.  
According to the CDC, African American women have the highest rates of new HIV infections 
and low rates of PrEP use among women 5,18, therefore promoting PrEP use among African 
American women with appropriately targeted interventions can increase PrEP usage.   
With the increasing HIV incidence rates in some subpopulations, especially African 
American and Latino/Hispanic MSM, PrEP usage must increase drastically in these 
subpopulations to put a dent in the incidence of HIV and avoid possible outbreaks. 
To ensure that PrEP is successful in the future, simultaneous data collection and 
interventions that target increased PrEP use aimed at PrEP needy populations must be carried 
out.  PrEP to Need ratios can then be calculated to assess PrEP’s impact on reducing new HIV 
cases. A parallel increase in PrEP use and the PrEP to Need ratio could be an indication of PrEP 
use leading to a decrease in the number of new HIV cases. According to a study done by Siegler 
et. al, the first step in calculating PrEP to Need ratios is to calculate the number of PrEP users 
and determine the distribution of PrEP use among different populations27. PrEP to Need ratios of 
a particular region carried out periodically can give us trends on the effect of PrEP on new HIV 
cases. 
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Since PrEP along with other HIV preventive modalities are essential in the fight to 
eradicate HIV/AIDS, complete integration and recognition of PrEP as an effective HIV 
prevention modality is essential. Steps must also be taken to eradicate barriers to PrEP usage. 
Increasing access to PrEP, reducing the stigma surrounding PrEP, decreasing the costs associated 
with PrEP and educating medical professionals to increase PrEP prescription are some barriers 
that need to be addressed.  
Increasing insurance cover to improve PrEP usage can overcome the most important 
barrier to PrEP, the cost. The production of the generic version of Truvada (once Truvada’s 
patent expires in 2021) should increase PrEP coverage. The production of long acting PrEP 
medications in the future can address issues with adherence (for example taking a shot once in 
three months or having a depot version of PrEP implanted could vastly improve adherence vs 
taking one pill a day)36.   
Being in a relationship and side effects due to PrEP were the most common reasons for 
PrEP discontinuation in the study. The management of said side effects has the potential to 
improve PrEP adherence. Five out of 15 (33.3%) of the individuals who discontinued PrEP did 
so due to side effects. This is similar to the percentage of people who discontinued PrEP due to 
concern of side effects in a study done by Holloway et al (33.3%) on 761 young MSM in 
California from July 2015 to August 2015 39.  
This study has its share of limitations. The use of convenience sampling limits the 
generalizability of this study. Since the surveys took place at events that were LGBTQ focused, 
rates of past or present PrEP use and awareness were probably higher at these events compared 
to real-world overall rates, thus skewing the results of the study towards higher levels of past or 
present PrEP usage.  
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Not including individuals below the age of 18 also potentially eliminated past or present 
PrEP users below that age group ( FDA approved the use of Truvada in adolescents in 201825).  
Factors such as education level, income and health insurance can also influence the use of PrEP, 
unfortunately these factors were not controlled for in this study. Stigma associated with the 
personal nature of some of the survey questions could have also introduced a potential reporting 
bias. 
HIV status of the individual was unknown due to patient privacy/identity concerns, as 
being HIV positive would eliminate an individual from participating in this study since HIV 
positive individuals cannot use PrEP. Future research can include the HIV status of individuals 
in the study to accurately identify individuals who are PrEP eligible.  
The study did not account for individuals who may have taken the survey more than 
once. Individuals who may have filled out duplicate surveys while attending both Pride days 
and/or the Pride and the Too Hot for July events were not accounted for. 
The study also did not track the number of individuals who declined the survey. 
The population of this study was predominantly on the younger side. This could be attributed to 
the fact that the Too Hot for July event attracts a much younger crowd, skewing the population 
curve. The sample size of the study is also a limitation. A smaller sample size increases the 
margin of error and decreases generalizability. 
To improve on this study, future works should include a population that is more 
representative of the venue in which the study is being carried out in. This can be achieved by 
time-location sampling of the venue (a probabilistic method used to collect data on hard to reach 
populations – like MSM, who can be found at identifiable locations)40.  
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5.0 Conclusion 
PrEP is not being used by subpopulations that need HIV prevention the most. 
Subpopulations with the highest HIV incidences are not seeing increase in PrEP usage to levels 
that can positively impact HIV incidence rates. 
To assess the impact of PrEP on the community, data on PrEP usage is needed. There  is 
limited data on PrEP usage patterns among different demographic subgroups in Pittsburgh. This 
study attempts to gather  data on the demographic distribution of past or present PrEP use in 
Pittsburgh and compare it to national PrEP usage to fill in the gaps due to limited local data. PrEP 
to Need ratios can be calculated using PrEP usage statistics to determine the impact of PrEP on 
new HIV cases. The data in this and other similar studies is essential in calculating PnRs. The data 
from this study can also be used to assess trends in PrEP usage when paired with data from other 
studies looking at PrEP use over the years. 
Despite its limitations, this study aims to provide information on demographic variables 
that may be significantly associated with PrEP use.  
Convenience sampling was used for its cost effectiveness and ease of use properties.  
Studies in the future can expand on this project by utilizing a larger sample size, acquiring 
a sample that is representative of the population being studied and filter out ineligible participants 
with more precision. The data in this study can be used as a point of reference for future studies 
that aim to gather data on PrEP use in Pittsburgh. 
To improve on this study, future works should include a population that is more 
representative of the venue in which the study is being carried out in. This can be achieved by 
time-location sampling of the venue (a probabilistic method used to collect data on hard to reach 
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populations – like MSM, who can be found at identifiable locations)40. Calculation of PrEP to 
need ratios for Pittsburgh is also a logical next step. Other recommendations for similar studies in 
the future would be to include the HIV status of individuals involved and use electronic surveys 
that are easier to use and provide more privacy to survey participants. 
PrEP for HIV is still a relatively new modality used in HIV prevention. With time and the 
appropriate effective intervention strategies to improve usage, PrEP will have a positive impact on 
HIV incidence levels. 
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